For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1263/Antiemetic-Drugs-World-Industry-and-Market-Analysis-2014-2024

1. Antiemetic Drugs:
World Industry and Market Analysis
2014-2024
©notice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior
written agreement of visiongain.You cannot photocopy, fax, download to database or duplicate in any other way
any of the material contained in this report. Each purchase and single copy is for personal use only.

2. www.visiongain.com
Contents
1.1 Antiemetic Drug Treatments: World Market Review
1.2 Content of Report Chapters
1.3 Research and Analysis Methods
2.1 What is Emesis?
2.1.1 The Process of Emesis: The Role of the Vomiting Centre
2.2 Causes and Complications of Vomiting Vary
2.2.1 Most Common Triggers of Vomiting
2.3 Diagnosing Emesis: Multidisciplinary Approach Required
2.4 Treating Emesis and The Approach to Pharmacological Management
2.4.1 Serotonin (5-HT3
) Antagonists: Gold Standard Treatment
2.4.2 Cannabinoids: Controversial Choice, But Interest Remains
2.4.3 Dopamine Antagonists: Effective in Post-Operative Setting
2.4.4 Other Therapies
3.1 The Global Antiemetic Drug Market, 2013
3.1.1 Leading Antiemetic Drugs, 2013
3.2 The Global Antiemetic Drug Market: Revenue Forecast, 2014-2024
3.2.1 What Will Drive The Global Antiemetic Drug Market Between 2014 and 2024?
1. Overview of Report
2. Introduction to Emesis and Antiemetic Drugs
3. The Global Antiemetic Drug Market, 2014-2024

3. www.visiongain.com
Contents
3.2.1.1 Growing Incidence of Cancer and Other Diseases
3.2.1.2 Increased Research Efforts Focused on New Therapies
3.2.1.3 Identifying New Drug Targets Through Technology
3.2.1.4 Launch of Novel Delivery Methods to Encourage Patient Compliance
3.2.2 What Factors are Likely to Restrain The Global Antiemetic Drug Market Between 2014
and 2024?
3.2.2.1 Improvements Needed in Design of Antiemetic Clinical Trials
3.2.2.2 High Cost of Alternative Animal Models
3.3 How Will the Market Shares of Leading Antiemetic Drug Classes Change From 2014-2024?
4.1 The 5-HT3
Antagonists Drug Market, 2013
4.2 The 5-HT3
Antagonists Drug Market: Revenue Forecast, 2014-2024
4.2.1 The 5-HT3
Antagonists Drug Market: Industry Trends, 2014-2024
4.3 The 5-HT3
Antagonists Drug Market: Revenue Forecasts of Leading Drugs, 2014-2024
4.3.1 Palonosetron (Aloxi®): Revenue Forecast, 2014-2024
4.3.2 Ondansetron (Zofran®): Revenue Forecast, 2014-2024
4.3.3 Granisetron (Sancuso®): Revenue Forecast, 2014-2024
4.3.4 Dolasetron (Anzemet®): Revenue Forecast, 2014-2024
4.4 How Will Market Shares of Leading 5-HT3
Antagonist Drugs Change from 2014-2024?
5.1 The Cannabinoids Drug Market, 2013
5.2 The Cannabinoids Drug Market: Revenue Forecast, 2014-2024
4. The 5-HT3 Antagonists Drug Market, 2014-2024
5. The Cannabinoids Drug Market, 2014-2024

4. www.visiongain.com
Contents
5.2.1 The Cannabinoids Drug Market: Industry Trends, 2014-2024
5.3 The Cannabinoids Drug Market: Revenue Forecast by Leading Drugs, 2014-2024
5.3.1 Dronabinol (Marinol®): Revenue Forecast, 2014-2024
5.3.2 Nabilone (Cesamet®): Revenue Forecast, 2014-2024
5.4 How Will the Market Shares of Leading Cannabinoid Drugs Change from 2014-2024?
6.1 The Dopamine Antagonists Drug Market, 2013
6.2 The Dopamine Antagonists Drug Market: Revenue Forecast, 2014-2024
6.2.1 The Dopamine Antagonists Drug Market: Industry Trends, 2014-2024
6.3 The Dopamine Antagonists Drug Market: Revenue Forecast by Leading Drugs, 2014-2024
6.3.1 Metoclopramide (Reglan®): Revenue Forecast, 2014-2024
6.3.2 Domperidone (Motilium®): Revenue Forecast, 2014-2024
6.4 How Will Market Shares of Leading Dopamine Antagonist Drugs Change from 2014-2024?
7.1 Leading National Markets for Antiemetic Drugs, 2013
7.2 The Global Antiemetic Drug Market: Revenue Forecasts by Region, 2014-2024
7.3 The US Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.3.1 Novel Drug Formulation to Increase Compliance
7.4 The Antiemetic Drug Market in Leading EU Countries (EU5), 2013
7.4.1 The Antiemetic Drug Market in The EU5: Revenue Forecasts by Country, 2014-2024
7.4.1.1 The German Antiemetic Drug Market: Revenue Forecast, 2014-2024
6. The Dopamine Antagonists Drug Market, 2014-2024
7. Leading National Markets for Antiemetic Drugs, 2014-2024

5. www.visiongain.com
Contents
7.4.1.2 The French Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.4.1.3 The UK Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.4.1.4 The Italian Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.4.1.5 The Spanish Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.5 The Japanese Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.6 The Russian Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.7 The Chinese Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.7.1 Strong Incentives Prompt Entry of New Companies
7.7.2 Multi-Billion Dollar Investment to Improve Healthcare
7.8 The Indian Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.8.1 Difficulties in Drug Distribution May Restrict Market
7.9 The Brazilian Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.9.1 Restrictions on Foreign Companies May Stifle Market Growth
8.1 Discovering New Treatments and Molecular Targets
8.2 Targeting Serotonin: Expanding on the Clinical Success of 5-HT3
Antagonists
8.2.1 Sustol (APF-530; Heron Therapeutics): Enhanced Duration of Action
8.2.2 RHB-102 (RedHill Biopharma): Consistent Bioequivalency with Marketed Therapy
8.2.3 ETI-385 (Epiomed): Aiming to Target Multiple Emesis Pathways
8.3 Cannabinoids: R&D Pipeline Developments
8.3.1 Dronabinol Oral Solution (INSYS Therapeutics): Improved Bioavailability
8.4 Dopamine Antagonists: R&D Pipeline Developments
8.4.1 APD421 (Acacia Pharma): New Indication for Drug?
8. The Antiemetic Drug Market: R&D Pipeline, 2014

6. www.visiongain.com
Contents
8.4.2 APD403 (Acacia Pharma): Potential Market Leader?
8.5 Other Novel Drugs Under Development
8.5.1 NK1 Receptor Antagonists
8.5.1.1 Netupitant-Palonosetron (Helsinn Healthcare): Dual Drug Combination
8.5.1.2 Rolapitant (OPKO Health/TESARO): Therapy Offering Prolonged, 5-day Effect
8.5.1.3 Vestipitant (GW597599; GSK): Applications in Numerous Therapeutic Areas?
8.5.2 Antihistamines
8.5.2.1 CL-108 (Charleston Laboratories): Targeting Emesis and Pain
8.5.3 Non-Pharmacological Therapies
8.5.3.1 Zindol (Aphios Corporation): Ginger-based Therapy
9.1 SWOT Analysis of The Global Antiemetic Drug Market, 2014-2024
9.2 Strengths
9.2.1 The Drive to Discover a Universal Therapy
9.2.2 Varied Market Landscape Containing Big and Small Players
9.3 Weaknesses
9.3.1 Antiemetic Trials Need Overhaul
9.4 Opportunities
9.4.1 Global Increase in Cancer Prevalence
9.4.2 Secondary Indications Encourage Companies to Enter Market
9.5 Threats
9.5.1 Concerns of Cardiac Side Effects of Market-Leading Drugs
9.5.2 Wearable Devices: Stimulating Neural Emesis Pathways
9. World Antiemetic Drug Market: Industry Trends, 2014-2024

7. www.visiongain.com
Contents
9.6 STEP Analysis of The Global Antiemetic Drug Market, 2014-2024
9.6.1 Social Factors
9.6.2 Technological Advances
9.6.3 Economic Pressures
9.6.4 Political Issues
10.1 Interview with a Respondent from a Company Marketing Antiemetic Therapies
10.1.1 The Current Antiemetic Drug Market and Demand in the Asia-Pacific Region
10.1.2 Market Competition and Common Diseases Triggering Emesis
10.1.3 Current and Future Directions for Antiemetic Therapy
11.1 The Global Antiemetic Drug Market - Current Status
11.2 Outlook for The Global Antiemetic Drugs Market, 2014-2024
11.2.1 5-HT3
Antagonists Will Continue to Dominate the Market
11.2.2 Regional Outlook for the Antiemetic Drugs Market, 2014-2024
About Visiongain’s Bespoke Research Service
Appendix A: About Visiongain
Appendix B: Visiongain Report Evaluation Form
10. Research Interview
11. Conclusions
Appendices

8. Page 31www.visiongain.com
Antiemetic Drugs: World Industry
and Market Analysis 2014-2024
3.2.1 What Will Drive The Global Antiemetic Drug Market Between
2014 and 2024?
3.2.1.1 Growing Incidence of Cancer and Other Diseases
The market for antiemetic drugs is predicted to grow strongly, primarily in line with the global
increase in the incidence of cancer. Although nausea and emesis can result from surgery,
opiates, or radiotherapy, CINV is the most severe and distressing. In patients receiving highly
emetogenic chemotherapy, more than 60% of them are likely to experience nausea and
emesis. High risk chemotherapeutic agents (causing emesis in more than 90% of patients)
include cisplatin and carmustine. While the outcome for patients suffering for CINV has
significantly improved in recent years, this particular side effect still has an impact on patients’
quality of life and can interfere with the ability to deliver intensive care. For this reason, there is
still high demand for newer antiemetic therapies, not just in the post-chemotherapy setting, but
also treating emesis immediately prior to chemotherapy treatment. This phenomenon - known
• Increasing incidence of cancer and
CINV
• Growing research efforts to discover
a universal antiemetic therapy
• Advancements in technology to
discover new potential drug targets
• Introduction of novel delivery
methods to improve patient
compliance
Drivers Restraints
• Design of antiemetic clinical trials
needs overhaul
• Lack of appropriate animal models
that mimics human response to
emetic treatments (costly alternatives
therefore have to be used)
Figure 3.5 The Global Antiemetic Drug Market: Drivers and Restraints, 2014-2024
Source: visiongain 2014

9. Page 51www.visiongain.com
Antiemetic Drugs: World Industry
and Market Analysis 2014-2024
5.2 The Cannabinoids Drug Market: Revenue Forecast, 2014-2024
Table 5.2 shows the market forecast for cannabinoid drugs from 2014-2024, by leading drugs.
Valued at $294.2m in 2013, the market is predicted to grow to $401.1m in 2018 (CAGR from
2013, 6.4%) and to $557.8m in 2024 (CAGR 2018-2024, 5.7%), according to visiongain
0.0
50.0
100.0
150.0
200.0
Dronabinol Nabilone Others
Revenue($m)
Drug
Dronabinol, 55.3%
Nabilone, 24.9%
Others, 19.7%
Figure 5.1 The Cannabinoids Drug Market: Revenue ($m) by Leading Drug, 2013
Figure 5.2 The Cannabinoids Drug Market: Market Shares (%) by Leading Drug,
2013
Source: visiongain 2014
Source: visiongain 2014

10. Page 64www.visiongain.com
Antiemetic Drugs: World Industry
and Market Analysis 2014-2024
Revenue for domperidone amounted to $72.9m in 2013. Visiongain predicts revenues will
reach $99.8m in 2018 and $109.2m in 2024. Table 6.4 and Figure 6.5 show the revenue
performance of domperidone from 2014-2024.
2013 2014 2015 2016 2017 2018
Domperidone ($m) 72.9 76.2 80.8 85.6 91.6 99.8
Annual Growth (%) 5 6 6 7 9
CAGR (%, 2013-2018) 6.5
2019 2020 2021 2022 2023 2024
Domperidone ($m) 109.8 115.3 119.9 122.3 116.2 109.2
Annual Growth (%) 10 5 4 2 -5 -6
CAGR (%, 2018-2024) 1.5
CAGR (%, 2013-2024) 3.7
0.0
20.0
40.0
60.0
80.0
100.0
120.0
140.0
Revenue($m)
Year
Table 6.4 Domperidone: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Figure 6.5 Domperidone: Revenue Forecast ($m), 2014-2024
Source: visiongain 2014
Source: visiongain 2014